Australia vs Germany: The number of people with susceptibility test result for rifampicin
Australia
83.5
in 2021
Germany
83.72
in 2021
Australia rank
90th
Germany rank
89th
The number of people with susceptibility test result for rifampicin over time
- Australia
- Germany
How they compare
Germany currently reports 83.72 against 83.5 in Australia, a difference of 0.22.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Australia ahead.
Australia ranks 90th and Germany ranks 89th of 146 countries.
Australia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Australia | Germany | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 92.62 | 87.11 | 5.5 | Australia |
| 2020s | 88.8 | 84.9 | 3.9 | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Australia or Germany?
- Germany, at 83.72 against 83.5 in Australia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Australia and Germany?
- 0.22, with Germany ahead.
- How many years of comparable data are there for Australia and Germany?
- 5 years are reported by both, from 2017 to 2021.
- How do Australia and Germany rank globally for the number of people with susceptibility test result for rifampicin?
- Australia ranks 90th and Germany ranks 89th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.